Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01035983
Other study ID # VML 251-3MAM03
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 2003
Est. completion date June 2005

Study information

Verified date December 2023
Source Endo Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this open-label, multi-center study, patients were treated with frovatriptan for a maximum of 12 perimenstrual periods (PMPs). For each PMP, dosing commenced 2 days before the anticipated onset of the menstrual migraine (MM) headache and continued for a total of 6 days. Patients were to take a loading dose of frovatriptan 5 mg (two tablets) twice daily on Day 1, followed by frovatriptan 2.5 mg twice daily on Days 2-6. During the study, patients were to visit the study site a total of 6 times. Efficacy and/or safety assessments were performed at each visit.


Description:

This Phase IIIb, open label, multi-centre study evaluated the safety and tolerability of frovatriptan taken by patients for up to 12 perimenstrual periods (PMPs) for the prevention of menstrual migraine (MM). The study required approximately 300 patients to treat 6 PMPs and 100 patients to treat 12 PMPs. To achieve these numbers, 550 patients were to be enrolled into the study. Once enrolled, patients were requested to treat at least 6 PMPs in the first 9 months and 12 PMPs overall. Patients were to remain in the study for a maximum of 15 months or until they had completed the treatment of 12 PMPs, whichever occurred sooner.Patients were to take a loading dose of frovatriptan 5 mg (two tablets) twice daily on Day 1, followed by frovatriptan 2.5 mg twice daily on Days 2-6.


Recruitment information / eligibility

Status Completed
Enrollment 550
Est. completion date June 2005
Est. primary completion date June 2005
Accepts healthy volunteers No
Gender Female
Age group 15 Years and older
Eligibility Inclusion Criteria: - Female aged 15 years and over (=18 years in United Kingdom and South Africa), with at least a 12 month documented history of experiencing migraine according to IHS criteria, including confirmation of a 3 month diary based documented history of MAM. - An average frequency of MAM in at least two out of three menstrual cycles, within the previous 12 months - Regular, predictable menstrual periods - MAM headaches occurring between Day -2 and day +4 of menses - Able and willing to sign informed consent and to comply with study procedures, including completion of the diary cards. Exclusion Criteria: - More than three migraine attacks per month that were not MAM attacks - A history of myocardial infarction, ischemic heart disease (or presenting with symptoms or signs compatible with ischemic heart disease), coronary vasospasm or peripheral vascular disease - Significant cerebrovascular disease including basilar or hemiplegic migraine - Uncontrolled hypertension (SBP >180 mmHg, DBP >95 mmHg) - Severe hepatic or renal insufficiency - More than 15 headache days per month, exclusive of migraine headache - Any other condition or serious illness which, in the opinion of the investigator, would interfere with optimal participation in the study - A history of clinically relevant allergy, including that to frovatriptan or other triptans - Pregnant or breast-feeding, or intending to become pregnant or breast-feed during the study period (patients were to be using adequate contraception and have a negative pregnancy test at screening) - Treatment with another investigational drug within 30 days or 5 half-lives (whichever was longer) before the screening visit - Any change in their oral contraceptive medication (if applicable) in the 2 months prior to screening, or anticipation of any change during study participation - Any change in the type or dose of any prophylactic migraine medication in the 2 months prior to screening, or anticipation of any change during study participation - A history of migraine with aura, according to IHS criteria, and currently treated with a combined oral contraceptive (South Africa only).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Frovatriptan 2.5 mg


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Endo Pharmaceuticals Vernalis (R&D) Ltd

Countries where clinical trial is conducted

Germany,  Hungary,  Poland,  South Africa,  United Kingdom, 

References & Publications (1)

MacGregor EA, Brandes JL, Silberstein S, Jeka S, Czapinski P, Shaw B, Pawsey S. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache. 2009 Oct;49(9):1298-314. doi: 10.1111/j.1526-4610.2009.01513.x. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of all treatment-emergent adverse events (AEs). 9-15 months
Secondary Incidence of menstrual migraine headache 9-15 months
Secondary Maximum headache severity 9-15 months
Secondary Number of headache-free days during a treated perimenstrual period (PMP) 9-15 months
Secondary Occurrence and severity of menstrual migraine headache-associated symptoms 9-15 months
Secondary Maximum functional impairment during menstrual migraine headache 9-15 months
Secondary Incidence and severity of intercurrent migraine 9-15 months
Secondary Total migraine burden 9-15 months
Secondary Standard hematology and biochemistry 9-15 months
Secondary 12-lead electrocardiogram (ECG) and vital signs, physical examination 9-15 months
Secondary Short-form 12 (SF-12) Health Related Quality of Life Questionnaire 9-12 months
See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A